Prosecution Insights
Last updated: November 16, 2026
Application No. 19/017,017

HIGH FREQUENCY STIMULATION FOR TREATING SENSORY AND/OR MOTOR DEFICITS IN PATIENTS WITH SPINAL CORD INJURIES AND/OR PERIPHERAL POLYNEUROPATHY, AND ASSOCIATED SYSTEMS AND METHODS

Final Rejection §103§DOUBLEPATENT
Filed
Jan 10, 2025
Priority
Jan 19, 2017 — provisional 62/448,320 +4 more
Examiner
SAHAND, SANA
Art Unit
3792
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Nevro Corp.
OA Round
2 (Final)
64%
Grant Probability
Moderate
3-4
OA Rounds
87%
With Interview

Examiner Intelligence

Grants 64% of resolved cases
64%
Career Allowance Rate
230 granted / 359 resolved
-5.9% vs TC avg
Strong +23% interview lift
Without
With
+22.9%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
66 currently pending
Career history
444
Total Applications
across all art units

Office Action

§103 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Arguments Applicant’s arguments in combination with amendments, see remarks and claims, filed 09/08/2026, , with respect to rejections of claims under 35 USC 101 have been fully considered and are persuasive. The 101 rejections of claims has been withdrawn. Applicant’s arguments in combination with amendments, see remarks and claims, filed 09/08/2026, , with respect to rejections of claims under 35 USC 103 have been fully considered and are persuasive. Therefore, the rejection has been withdrawn. However, upon further consideration, a new ground(s) of rejection is made further in view of US 20130066411 to Thacker et al. See detailed rejection below. The applicant has not responded to the double patenting rejections in their response. The double patenting rejections has been repeated below. See detailed rejection below. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims is/are rejected under 35 U.S.C. 103 as being unpatentable over Chitre et al., (US 20100274326; hereinafter Chitre) in view of Thacker et al. (US 20130066411 to Thacker). Regarding claim 31. (New) Chitre discloses a method of treating a patient having sensation loss (para 0090), via spinal cord stimulation (para 0090, fig. 1), the method comprising:, programming a signal generator to deliver a non-photonic, non-paresthesia producing electrical signal (para 0027 “use the external programmer 105 to vary the modulation parameters provided to the signal delivery element 110”, providing high frequency stimulation via the lead is understood to be non-photonic, non-paresthesia) having a frequency in a frequency range of 1.2 kHz to 100 kHz (para 0035, 0046, 0048, 0078 “the frequency of the signal (or at least a portion of the signal) can be from about 1.5 kHz to about 100 kHz”) to the patient's spinal cord via at least one implanted signal delivery element (abstract, para 0005, 0022, etc.), but fails to disclose wherein the non-paresthesia producing electrical signal at least partially restores the sensation that was lost, and wherein the sensation was lost in association with diabetic neuropathy. Chitre does not explicitly disclose at least partially in response to the patient having the sensation loss [performing the steps above at the high frequency] and wherein the non-paresthesia producing electrical signal at least partially restores the sensation that was lost, and wherein the sensation was lost in association with diabetic neuropathy. It is noted that the claim does not provide any details regarding how the patient is identified to have sensation loss. Therefore, any patient being treated is understood to have sensation loss. Thacker, from a similar field of endeavor, teaches an implantable spinal cord modulation system positioned at the spine to deliver therapeutic signals (para 0005) for inhibiting pain via waveforms with high frequency (para 0023, 0025, 0036) and the patient diabetic truncal neuropathy to be treated using the T1-T12 modulation target (table 1). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify Chitre with the teachings of Thacker such that the method is for treating a patient having diabetic truncal neuropathy. Regarding claim 32. (New) Chitre as modified by Thacker renders obvious the method of claim 31 wherein the signal generator is implantable (Chitre para 0022), the at least one implanted signal delivery element is positioned in the patient's thoracic vertebral region between T8 and T12 (Chitre, para 0090 “vertebral levels T9, T10, T11, and/or T12”), and the non-paresthesia producing electrical signal has (a) a pulse width in a pulse width range of 10 microseconds to 333 microseconds (Chitre para 0076 “The pulse width (e.g., for just the cathodic phase of the pulses) can vary from about 10 microseconds to about 333 microseconds”), and (b) an amplitude in an amplitude range of 0.5 milliamps to 10 milliamps (Chitre para 0022, 0046, 0048, 0076). Regarding claim 33. (New) Chitre as modified by Thacker renders obvious the method of claim 31 wherein the frequency range is from 3 kHz to 20 kHz (Chitre para 0022, 0046, 0048, 0076; Thacker, para 0038; “[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955)). Regarding claim 34. (New) Chitre as modified by Thacker renders obvious the method of claim 31 wherein the non-paresthesia producing electrical signal has a pulse width in a pulse width range of 10 microseconds to 333 microseconds (Chitre para 0076 “The pulse width (e.g., for just the cathodic phase of the pulses) can vary from about 10 microseconds to about 333 microseconds”; Thacker, para 0078; "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955)). Regarding claim 35. (New) Chitre as modified by Thacker renders obvious the method of claim 31 wherein the non-paresthesia producing electrical signal has a pulse width in a pulse width range of 25 microseconds to 35 microseconds (para 0035 “The width of the applied pulses was about 30-35 microseconds”, Thacker, para 0078;; "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955)). Regarding claim 36. (New) Chitre as modified by Thacker renders obvious the method of claim 31 wherein the non-paresthesia producing electrical signal has an amplitude in an amplitude range of 0.5 milliamps to 10 milliamps (Chitre para 0022, 0046, 0048, 0076). Regarding claim 37. (New) Chitre as modified by Thacker renders obvious the method of claim 31 wherein the at least one implanted signal delivery element is positioned in the patient's thoracic vertebral region Chitre, para 0090). Regarding claim 38. (New) Chitre as modified by Thacker renders obvious the method of claim 37 wherein the at least one implanted signal delivery element is positioned in the patient's thoracic vertebral region between T8 and T12, inclusive (Chitre, para 0090 “vertebral levels T9, T10, T11, and/or T12”; Thacker, table 1). Regarding claim 39. (New) Chitre as modified by Thacker renders obvious the method of claim 31 wherein the at least one implanted signal delivery element is positioned in the patient's epidural space (Chitre, para 0092; Thacker, para 0097). Regarding claim 40. (New) Chitre as modified by Thacker renders obvious the method of claim 31 wherein the sensation loss is in the patient's f or leg, and wherein the non-paresthesia producing electrical signal at least partially restores the sensation that was lost in the patient's foot or leg (see rejection of claim 31). Regarding claim 41. (New) Chitre as modified by Thacker renders obvious the method of claim 31 wherein the non-paresthesia producing electrical signal at least partially alleviates extremity pain associated with the diabetic neuropathy in addition to restoring the sensation (see rejection of claim 31; Thacker, table 1, para 0023, 0097, claim 1, etc.). Regarding claim 42. (New) Chitre as modified by Thacker renders obvious the method of claim 31 wherein the non-paresthesia producing electrical signal at least partially eliminates sensations of tingling, pins-and-needles, and/or electric shock associated with the diabetic neuropathy, in addition to at least partially restoring the sensation (see rejection of claim 31; Thacker, table 1). Regarding claim 43. (New) Chitre as modified by Thacker renders obvious the method of claim 31 wherein the sensation lost in association with the diabetic neuropathy includes sensation loss caused by diabetes (see rejection of claim 31; Thacker, table 1). Regarding claim 44. (New) Chitre discloses method of treating a patient having a loss of sensation (para 0090), via spinal cord stimulation (para 0090, fig. 1), the method comprising: programming a signal generator to deliver (para 0027 “use the external programmer 105 to vary the modulation parameters provided to the signal delivery element 110”), via at least one implanted signal delivery element (abstract, para 0005, 0022, etc.), a non-paresthesia producing electrical signal having a frequency in a frequency range of 1.2 kHz to 100 kHz to the patient's spinal cord (para 0035, 0046, 0048, 0078 “the frequency of the signal (or at least a portion of the signal) can be from about 1.5 kHz to about 100 kHz”) but fails to disclose wherein the non-paresthesia producing electrical signal at least partially restores the sensation that was lost, and wherein the sensation was lost in association with diabetic neuropathy. Chitre does not explicitly disclose at least partially in response to the patient having the sensation loss [performing the steps above at the high frequency] and wherein the non-paresthesia producing electrical signal at least partially restores the sensation that was lost, and wherein the sensation was lost in association with diabetic neuropathy. It is noted that the claim does not provide any details regarding how the patient is identified to have sensation loss. Therefore, any patient being treated is understood to have sensation loss. Thacker, from a similar field of endeavor, teaches an implantable spinal cord modulation system positioned at the spine to deliver therapeutic signals (para 0005) for inhibiting pain via waveforms with high frequency (para 0023, 0025, 0036) and the patient diabetic truncal neuropathy to be treated using the T1-T12 modulation target (table 1). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify Chitre with the teachings of Thacker such that the method is for treating a patient having diabetic truncal neuropathy. Regarding claim 45. (New) Chitre as modified by Thacker renders obvious the method of claim 44 wherein the signal generator is implantable, the at least one implanted signal delivery element is positioned in the patient's thoracic vertebral region between T8 and T12 (Chitre, para 0090 “vertebral levels T9, T10, T11, and/or T12”), and the non-paresthesia producing electrical signal has (a) a pulse width in a pulse width range of 10 microseconds to 333 microseconds (Chitre para 0076 “The pulse width (e.g., for just the cathodic phase of the pulses) can vary from about 10 microseconds to about 333 microseconds”), and (b) an amplitude in an amplitude range of 0.5 milliamps to 10 milliamps (Chitre para 0022, 0046, 0048, 0076; Thacker, para 0078). Regarding claim 46. (New) Chitre as modified by Thacker renders obvious the method of claim 44 wherein the frequency range is from 2 kHz to 50 kHz (Chitre para 0022, 0046, 0048, 0076; Thacker 94, "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955)). Regarding claim 47. (New) Chitre as modified by Thacker renders obvious the method of claim 44 wherein the non-paresthesia producing electrical signal has (a) a pulse width in a pulse width range of 10 microseconds to 333 microseconds (Chitre para 0076 “The pulse width (e.g., for just the cathodic phase of the pulses) can vary from about 10 microseconds to about 333 microseconds”), and (b) an amplitude in an amplitude range of 0.5 milliamps to 10 milliamps (Chitre para 0022, 0046, 0048, 0076; Thacker, para 0078). Regarding claim 48. (New) Chitre as modified by Thacker renders obvious the method of claim 44 wherein the non-paresthesia producing electrical signal has (a) a pulse width in a pulse width range of 25 microseconds to 35 microseconds (para 0035 “The width of the applied pulses was about 30-35 microseconds”, 0076; "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955)), and (b) an amplitude in an amplitude range of 0.5 milliamps to 10 milliamps (Chitre para 0022, 0046, 0048, 0076; Thacker para 0094). Regarding claim 49. (New) Chitre as modified by Thacker renders obvious the method of claim 44 wherein the at least one implanted signal delivery element is positioned in the patient's thoracic vertebral region between T8 and T12 (Chitre, para 0090 “vertebral levels T9, T10, T11, and/or T12”; Thacker table 1), inclusive. Regarding claim 50. (New) Chitre as modified by Thacker renders obvious the method of claim 44 wherein the non-paresthesia producing electrical signal at least partially eliminates sensations of tingling, pins-and-needles, and/or electric shock associated with the diabetic neuropathy, in addition to at least partially restoring the sensation (see rejection of claim 44; Thacker, table 1). Regarding claim 51. (New) Chitre as modified by Thacker renders obvious the method of claim 44 wherein the sensation loss is in the patient's foot or leg, and wherein the non-paresthesia producing electrical signal at least partially restores the sensation that was lost in the patient's foot or leg (Thacker table 1; result of treatment). Regarding claim 52. (New) Chitre as modified by Thacker renders obvious the method of claim 44 wherein the non-paresthesia producing electrical signal at least partially alleviates extremity pain associated with the diabetic neuropathy in addition to restoring the sensation (see rejection of claim 44). Regarding claim 53. (New) Chitre as modified by Thacker renders obvious the method of claim 44 wherein the sensation lost in association with the diabetic neuropathy includes sensation loss caused by diabetes (Thacker table 1; result of treatment). Regarding claim 54. (New) Chitre discloses a method of treating a patient having sensation loss (para 0090), via spinal cord stimulation (para 0090, fig. 1), the method comprising: directing an electrical signal (para 0027 “use the external programmer 105 to vary the modulation parameters provided to the signal delivery element 110”) having a frequency in a frequency range of 1.2 kHz to 100 kHz (para 0035, 0046, 0048, 0078 “the frequency of the signal (or at least a portion of the signal) can be from about 1.5 kHz to about 100 kHz”) to the patient's spinal cord region via an implanted signal delivery element (abstract, para 0005, 0022, etc.), but fails to disclose wherein the non-paresthesia producing electrical signal at least partially restores the sensation that was lost, and wherein the sensation was lost in association with diabetic neuropathy. Chitre does not explicitly disclose at least partially in response to the patient having the sensation loss [performing the steps above at the high frequency] and wherein the non-paresthesia producing electrical signal at least partially restores the sensation that was lost, and wherein the sensation was lost in association with diabetic neuropathy. It is noted that the claim does not provide any details regarding how the patient is identified to have sensation loss. Therefore, any patient being treated is understood to have sensation loss. Thacker, from a similar field of endeavor, teaches an implantable spinal cord modulation system positioned at the spine to deliver therapeutic signals (para 0005) for inhibiting pain via waveforms with high frequency (para 0023, 0025, 0036) and the patient diabetic truncal neuropathy to be treated using the T1-T12 modulation target (table 1). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify Chitre with the teachings of Thacker such that the method is for treating a patient having diabetic truncal neuropathy. Regarding claim 55. (New) Chitre as modified by Thacker renders obvious the method of claim 54 wherein the electrical signal has (a) a pulse width in a pulse width range of 10 microseconds to 333 microseconds (Chitre para 0076 “The pulse width (e.g., for just the cathodic phase of the pulses) can vary from about 10 microseconds to about 333 microseconds”), and (b) an amplitude in an amplitude range of 0.5 milliamps to 10 milliamps (Chitre para 0022, 0046, 0048, 0076). Regarding claim 56. (New) Chitre as modified by Thacker renders obvious the method of claim 54 wherein the electrical signal at least partially alleviates sensations of tingling, pins-and-needles, and/or electric shock associated with the diabetic neuropathy, in addition to restoring the sensation (see rejection of claim 54; Thacker, table 1). Double Patenting Claims 31, 44, 54 rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 10, 11, 13, 17, 19, 23, 25, 28-29, 30 of U.S. Patent No. 11,986,657 Although the claims at issue are not identical, they are not patentably distinct from each other. Claims 31, 44, 54 rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 10, 11, 13, 17, 19, 21, 23, 26 of U.S. Patent No. 12,343,537 Although the claims at issue are not identical, they are not patentably distinct from each other. Claims 31, 44, 54 rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-5, 8-10, 22-24 of U.S. Patent No. 12,133,981 Although the claims at issue are not identical, they are not patentably distinct from each other. Claims 31-57 rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-5, 7-9, 13-18, 23-24 of U.S. Patent No. 12,226,634 Although the claims at issue are not identical, they are not patentably distinct from each other. Claim 31- 57 provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claim 1-28 of copending Application No. 17/672,447 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Claim 31- 57 provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claim 1-28 of copending Application No. 18/131,791 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Claim 31, 44, 54 provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claim 1, 15 and 29 of copending Application No. 18/916,512 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Claim 31, 44, 54 provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 5-6, 15-17of copending Application No. 19/239,029 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Claim 31, 44, 54 provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 9-10, 13, 17, 19 of copending Application No. 19/238,870 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Claim 31, 44, 54 provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 17, 24, 27-29, 32, 35-36 of copending Application No. 19/238,870 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Claim 31, 44, 54 provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claim 29, 34, 37, 4146, 51 of copending Application No. 17011908 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Claim 31, 44, 54 provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claim 29, 31-33, 38, 40, 44, 45-46, 50 of copending Application No. 18338285 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. It is noted that due to the large number of applications/patents, double patenting issues will be reassessed when the claims are in condition of allowance. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SANA SAHAND whose telephone number is (571)272-6842. The examiner can normally be reached M-Th 8:30 am -5:30 pm; F 9 am-3 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jennifer S McDonald can be reached at (571) 270- 3061. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SANA SAHAND/Examiner, Art Unit 3796
Read full office action

Prosecution Timeline

Jan 10, 2025
Application Filed
Jun 08, 2026
Non-Final Rejection mailed — §103, §DOUBLEPATENT
Sep 08, 2026
Response Filed
Oct 14, 2026
Final Rejection mailed — §103, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12788325
INTEGRATED PRESSURE TRANSDUCER FOR PRECISE QUANTIFICATION OF APPLIED SURFACE FORCE IN WEARABLE DEVICES
2y 10m to grant Granted Nov 10, 2026
Patent 12778519
COMPUTER-IMPLEMENTED METHOD FOR SYNCHRONIZING A PHOTOPLETHYSMOGRAPHY (PPG) SIGNAL WITH AN ELECTROCARDIOGRAM (ECG) SIGNAL
4y 2m to grant Granted Nov 03, 2026
Patent 12778475
SYSTEM AND METHOD FOR SPORTS MENTAL HEALTH FITNESS TRACKER
1y 10m to grant Granted Nov 03, 2026
Patent 12779210
TREMOR TREATMENT SYSTEMS USING VIBRATORY STIMULATION
11m to grant Granted Nov 03, 2026
Patent 12773145
SYSTEMS AND METHODS FOR EXAMINING HOLLOW ORGANS
2y 9m to grant Granted Oct 27, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
64%
Grant Probability
87%
With Interview (+22.9%)
Moderate
PTA Risk
Based on 359 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month